ZCA
VRPX

Zeke Capital Advisors’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Zeke Capital Advisors’s Portfolio VRPX Stock Details VRPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-180
Closed -$205K – 355
2021
Q2 		$205K Hold
180
– – 0.01% 299
2021
Q1 		$212K Buy
+180
New +$242K 0.01% 272

Other funds holding VRPX

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Zeke Capital Advisors's VRPX Position: Q3 2021 in Review

Zeke Capital Advisors sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q3 2021, closing a stake of 180 shares — an estimated $205K sold.

Zeke Capital Advisors first reported a position in VRPX in Q1 2021 and held it in 2 quarters. The position peaked at $212K in Q1 2021. 11 funds tracked by Wall St. Rank hold VRPX as of Q3 2021.

  • Zeke Capital Advisors reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Zeke Capital Advisors sold 180 Virpax Pharmaceuticals, Inc. Common Stock shares in Q3 2021, an estimated $205K.
  • Zeke Capital Advisors first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Zeke Capital Advisors's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $212K in Q1 2021.
  • 11 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q3 2021.

Based on Zeke Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.